Literature DB >> 16552069

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.

Liana Tsenova1, Ryhor Harbacheuski, Andre L Moreira, Evette Ellison, Wilfried Dalemans, Mark R Alderson, Barun Mathema, Steven G Reed, Yasir A W Skeiky, Gilla Kaplan.   

Abstract

Using a rabbit model of tuberculous meningitis, we evaluated the protective efficacy of vaccination with the recombinant polyprotein Mtb72F, which is formulated in two alternative adjuvants, AS02A and AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guérin (BCG) alone or as a BCG prime/Mtb72F-boost regimen. Vaccination with Mtb72F formulated in AS02A (Mtb72F+AS02A) or Mtb72F formulated in AS01B (Mtb72F+AS01B) was protective against central nervous system (CNS) challenge with Mycobacterium tuberculosis H37Rv to an extent comparable to that of vaccination with BCG. Similar accelerated clearances of bacilli from the cerebrospinal fluid, reduced leukocytosis, and less pathology of the brain and lungs were noted. Weight loss of infected rabbits was less extensive for Mtb72F+AS02A-vaccinated rabbits. In addition, protection against M. tuberculosis H37Rv CNS infection afforded by BCG/Mtb72F in a prime-boost strategy was similar to that by BCG alone. Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16552069      PMCID： PMC1418915          DOI： 10.1128/IAI.74.4.2392-2401.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  45 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Structural and immunological characterization of the vaccine adjuvant QS-21.

Authors:  C R Kensil; J Y Wu; S Soltysik
Journal:  Pharm Biotechnol       Date:  1995

3.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

Authors:  D C Dillon; M R Alderson; C H Day; D M Lewinsohn; R Coler; T Bement; A Campos-Neto; Y A Skeiky; I M Orme; A Roberts; S Steen; W Dalemans; R Badaro; S G Reed
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection.

Authors:  Y A Skeiky; P J Ovendale; S Jen; M R Alderson; D C Dillon; S Smith; C B Wilson; I M Orme; S G Reed; A Campos-Neto
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

Review 6.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001

7.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

Review 8.  Adjuvants for human vaccines--current status, problems and future prospects.

Authors:  R K Gupta; G R Siber
Journal:  Vaccine       Date:  1995-10       Impact factor: 3.641

9.  Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis.

Authors:  Lang Bao; Wei Chen; Huidong Zhang; Xiaoying Wang
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin.

Authors:  Sarah Young; Michael O'Donnell; Euan Lockhart; Bryce Buddle; Lynn Slobbe; Yi Luo; Geoff De Lisle; Glenn Buchan
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126
View more
  33 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

3.  Vaxar: A Web-Based Database of Laboratory Animal Responses to Vaccinations and Its Application in the Meta-Analysis of Different Animal Responses to Tuberculosis Vaccinations.

Authors:  Thomas Todd; Natalie Dunn; Zuoshuang Xiang; Yongqun He
Journal:  Comp Med       Date:  2016-04       Impact factor: 0.982

4.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

5.  Construction of Mtb72F Plasmid as a DNA Vaccine Candidate for Mycobacterium tuberculosis.

Authors:  Maryam Sadat Nabavinia; Mohammad Ramezani; Aida Gholoobi; Mahboubeh Naderinasab; Zahra Meshkat
Journal:  Rep Biochem Mol Biol       Date:  2017-10

6.  BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease.

Authors:  Liana Tsenova; Ryhor Harbacheuski; Nackmoon Sung; Evette Ellison; Dorothy Fallows; Gilla Kaplan
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

7.  Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.

Authors:  Isabel Leroux-Roels; Geert Leroux-Roels; Opokua Ofori-Anyinam; Philippe Moris; Els De Kock; Frédéric Clement; Marie-Claude Dubois; Marguerite Koutsoukos; Marie-Ange Demoitié; Joe Cohen; W Ripley Ballou
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

8.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Authors:  Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

9.  Novel vaccine strategies against tuberculosis: a road less travelled.

Authors:  Supriya Pokkali; Sanjay Jain
Journal:  Expert Rev Vaccines       Date:  2013-12       Impact factor: 5.217

10.  DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy.

Authors:  Andrea M Hebert; Sarah Talarico; Dong Yang; Riza Durmaz; Carl F Marrs; Lixin Zhang; Betsy Foxman; Zhenhua Yang
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.